XENE Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update

Xenon Pharmaceuticals to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Provide Corporate Update

BURNABY, British Columbia, July 30, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that it will report its second quarter 2020 financial and operating results after the close of U.S. financial markets on Thursday, August 6, 2020. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update.

To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 4056993. The webcast will be broadcast live on the “Investors” section of Xenon's website at and will be available for replay following the call for 30 days.

About Xenon Pharmaceuticals Inc.

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the

lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to

address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit -pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:

Jodi Regts

Xenon Pharmaceuticals Inc.

Phone: 604.484.3353

Email:

EN
30/07/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Xenon Pharmaceuticals Inc

 PRESS RELEASE

Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Bus...

Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026Five additional Phase 3 studies of azetukalner continue to enroll in epilepsy and neuropsychiatry indications with Phase 3 X-NOVA2 MDD topline data expected in H1 2027 Data from two Phase 1 studies of novel NaV1.7 (XEN1701) and KV7 (XEN1120) candidates expected in 2026 to support Phase 2 proof-of-concept studies in pain Pro forma cash of $716 million including recent ATM sales extends cash runway into second half of 2027Xenon...

Wedbush Research
  • Wedbush Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch